Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: JoeinIowa who wrote (1110)	1/20/2003 3:43:21 PM
From: JoeinIowa	Respond to of 23958

Alteon News. Press Release Source: Alteon Inc. Alteon Inc. Announces Investor Update Conference Call Tuesday, January 21, 2003, 2:00 P.M. Eastern Time Monday January 20, 12:58 pm ET RAMSEY, N.J., Jan. 20 /PRNewswire-FirstCall/ -- Alteon Inc. (Amex: ALT - News) announced today that it will hold an investor update conference call on Tuesday, January 21, 2003 at 2:00 p.m. eastern time which will include a discussion of preliminary results of the Phase IIa DIAMOND trial of ALT-711 in diastolic heart failure. Anyone interested in participating in the conference call should RSVP to Nancy Regan at 201-818-5877 (direct line), or email nregan@alteon.com. There will be a full question and answer period during the call. The call-in telephone number for the conference call will be 1-800-915-4836. International participants may call +973-317-5319. Participants should call approximately 5-10 minutes before 2:00 p.m. In addition, the conference call will be accessible through a webcast on the company website, alteon.com at the Investor Relations section, and a digital rebroadcast will be available through January 28, 2003 at 11:59 P.M. by dialing 1-800-428-6051, passcode 283288 for domestic callers and +973-709-2089, passcode 283288 for international callers. About Alteon Alteon is developing several new classes of drugs that reverse or slow down diseases of aging and complications of diabetes. These compounds have an impact on a fundamental pathological process caused by protein-glucose complexes called Advanced Glycosylation End-products (A.G.E.s). The formation and crosslinking of A.G.E.s lead to a loss of flexibility and function in body tissues, organs and vessels and have been shown to be a causative factor in many age-related diseases and diabetic complications. Alteon is initially developing therapies for cardiovascular and kidney diseases in older or diabetic individuals. Alteon has created a library of novel classes of compounds targeting the A.G.E. Pathway. These include A.G.E. Crosslink Breakers, A.G.E. Formation Inhibitors and Glucose Lowering Agents. The Company's lead A.G.E. Crosslink Breaker, ALT-711, is being evaluated in the Phase IIb SAPPHIRE clinical trial focused on patients with systolic hypertension, the Phase IIb SILVER trial in patients with systolic hypertension and left ventricular hypertrophy, and the Phase IIa DIAMOND trial in patients with diastolic heart failure. Other A.G.E. compounds are being evaluated for skin aging and additional indications. For more information on Alteon, visit the Company's web site at alteon.com. Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, those relating to technology and product development (including the possibility that early clinical trial results may not be predictive of results that will be obtained in large-scale testing or that any clinical trials will not demonstrate sufficient safety and efficacy to obtain requisite approvals or will not result in marketable products), regulatory approval processes, intellectual property rights and litigation, competitive products, ability to obtain financing, and other risks identified in Alteon's filings with the Securities and Exchange Commission. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Alteon undertakes no obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.